HCC827細胞

細胞形態(tài)： 上皮樣

數(shù)量： 大量

年限： 39 years *****

運輸方式： 凍存運輸

生長狀態(tài)： 貼壁生長

ATCC Number： CRL-2868?

相關(guān)**： 腺癌

細胞類型： 上皮細胞

器官來源： 肺

是否是腫瘤細胞： 0

物種來源： 人

Designations: HCC827

Depositors: AF Gazdar, JD Minna

HCC827細胞Biosafety Level: 1

Shipped: frozen

Medium & Serum: See Propagation

Growth Properties: adherent

Organism: Homo sapiens

Morphology: epithelial

Source: Organ: lung

Disease: adenocarcinoma

Cell Type: epithelial

Permits/Forms: In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.

Restrictions: The line is available with the following restrictions: 1. This cell line was deposited at the ATCC by Dr. A. Gazdar and Dr. J. Minna and is provided for research purposes only. Neither the cell line nor products derived from it may be sold or used for commercial purposes. Nor can the cells be distributed to third parties for purposes of sale, or producing for sale, cells or their products. The cells are provided as service to the research community. They are provided without warranty of merchantability or fitness for a particular purpose or any other warranty, expressed or implied. 2. HCC827細胞Any proposed commercial use of the these cells, or their products must first be negotiated with the University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Blvd., Dallas, Texas 75235. Telephone (214) 648-1888, Email TechnologyDevelopment@UTSouthwestern.edu, or Fax: (214) 951-0935.

Isolation: Isolation date: March 19, 1994

Age: 39 years *****

Gender: female

Ethnicity: Caucasian

Comments: This lung adenocarcinoma has an acquired mutation in the EGFR tyrosine kinase domain (E746 - A750 deletion).

Propagation: ATCC complete growth medium: The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, Catalog No. 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.

Atmosphere: air, 95%; carbon dioxide (CO2), 5%

Temperature: 37.0°C

Subculturing: Protocol:

HCC827細胞Remove and discard culture medium.

Briefly rinse the cell layer with or 0.25% (w/v) Trypsin - 0.53 mM EDTA solution or Dulbecco?s Phosphate Buffered Saline (D-PBS) to remove all traces of serum that contains trypsin inhibitor.

Add 1.0 to 3.0 ml of Trypsin-EDTA solution to flask and observe cells under an inverted microscope until the cell layer is dispersed (usually within 5 to 15 minutes).

Note: To avoid clumping do not agitate the cells by hitting or shaking the flask while waiting for the cells to detach. Cells that are difficult to detach may be placed at 37C to facilitate dispersal.

Add 6.0 to 8.0 ml of complete growth medium and aspirate cells by gently pipetting.

Transfer cell suspension to centrifuge tube and spin at approximately 125 x g for 5 to 10 minutes.

Discard supernatant and resuspend cells in fresh growth medium. Add appropriate aliquots of cell suspension to new culture vessels. An inoculum of 5 X 10(3) to 7 X 10(3) viable cells/sq. cm is recommended.

Place culture vessels in incubators at 37C. Maintain cultures at a cell concentration between 3 X 10(4) and 5 X 10(4) cells/sq. cm.

Subcultivation Ratio: A subcultivation ratio of 1:4 to 1:6 is recommended

Medium Renewal: Every 2 to 3 days

Preservation: Freeze medium: Complete growth medium supplemented with 5% (v/v) DMSO

Storage temperature: liquid nitrogen vapor phase

Doubling Time: 28 hours

Related Products: Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2001

recommended serum:ATCC 30-2020

0.25% (w/v) Trypsin - 0.53 mM EDTA in Hank' BSS (w/o Ca++, Mg++):ATCC 30-2101

phosphate-buffered saline:ATCC 30-2200

Cell culture tested DMSO:ATCC 4-X

References: 90786: Girard L, et al. HCC827細胞Genome-wide allelotyping of lung cancer identifies new regions of allelic loss, differences between small cell lung cancer and non-small cell lung cancer, and loci clustering. Cancer Res. 60: 4894-4906, 2000. PubMed: 10987304

90788: Burbee DG, et al. Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression. J. Natl. Cancer Inst. 93: 691-699, 2001. PubMed: 11333291

90789: Toyooka S, et al. Differential expression of FEZ1/LZTS1 gene in lung cancers and their cell cultures. Clin. Cancer Res. 8: 2292-2297, 0. PubMed: 12114433

90790: Virmani A, et al. Aberrant methylation of the cyclin D2 promoter in primary small cell, nonsmall cell lung and breast cancers. Int. J. Cancer 107: 341-345, 2003. PubMed: 14506731

90792: Liu CX, et al. LRP-DIT, a putative endocytic receptor gene, is frequently inactivated in non-small cell lung cancer cell lines. Cancer Res. 60: 1961-1967, 2000. PubMed: 10766186